col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


19 Results       Page 1

 [1] 
SAGE Publications: Therapeutic Advances in Drug Safety
  original article Date Title Authors   All Authors
1 [GO] 2026―Jan―02 Medication errors and associated serious outcomes in COVID-19 antivirals: a real-world study based on FDA Adverse Event Reporting System database Xiaomo Xiong, Zhanghe Chen, Bingfang Yan
2 [GO] 2024―Jan―28 Determinants of COVID-19 vaccine-induced myocarditis Jessica Rose, Nicolas Hulscher, Peter A. McCullough
3 [GO] 2023―May―22 Serious neurological adverse events following immunization against SARS-CoV-2: a narrative review of the literature Sara Eslait-Olaciregui, Kevin Llinás-Caballero, David Patiño-Manjarrés, Thomas Urbina-Ariza, Juan Fernando Cediel-Becerra, Camilo Alberto Domínguez-Domínguez
4 [GO] 2023―Mar―17 Impact of risk communication on patient’s safety during the pandemic Heyde-Patricia Zuluaga-Arias, Mayada Alkhakany, Manal M. Younus, Houda Sefiani, Angela Caro-Rojas, Sameh Al-Zubiedi, et al. (+2)
5 [GO] 2022―Dec―15 A survey on self-medication for the prevention or treatment of COVID-19 and distrust in healthcare of veterans in a primary care setting in the United States Eva Amenta, Larissa Grigoryan, Laura Dillon, Casey Hines-Munson, John Van, Barbara Trautner
6 [GO] 2022―Sep―05 Safety surveillance and challenges in accelerated COVID-19 vaccine development Abimbola Cole, Peggy Webster, Denny Van Liew, Maribel Salas, Omar Aimer, Marina A. Malikova
7 [GO] 2022―Aug―25 Global safety monitoring of COVID-19 vaccines: how pharmacovigilance rose to the challenge Annette Rudolph, Joseph Mitchell, Jim Barrett, Helena Sköld, Henric Taavola, Nils Erlanson, et al. (+2)
8 [GO] 2022―Aug―05 Risk communication on vaccines during the COVID19 pandemic: is there room for small size or private initiatives? An Israeli experience Irene R. Fermont, Ayalah Livneh, Michel Benhamou
9 [GO] 2022―Jul―21 Could chlorophyllins improve the safety profile of beta-d-N4-hydroxycytidine versus N-hydroxycytidine, the active ingredient of the SARS-CoV-2 antiviral molnupiravir? Nicole F. Clark, Andrew W. Taylor-Robinson, Kirsten Heimann
10 [GO] 2022―May―25 Prescription for COVID-19 by non-medical professionals during the pandemic in Colombia: a cross-sectional study Maria Jose Nino-Orrego, Daniela Baracaldo-Santamaría, Claudia Patricia Ortiz, Heyde Patricia Zuluaga, Sthefany Alejandra Cruz-Becerra, Franklin Soler, et al. (+3)
11 [GO] 2022―Apr―21 Drug safety of frequently used drugs and substances for self-medication in COVID-19 Daniela Baracaldo-Santamaría, Santiago Pabón-Londoño, Luis Carlos Rojas-Rodriguez
12 [GO] 2022―Mar―29 The response to the COVID-19 pandemic trusted in pharmacovigilance to diminish communication risk Gustavo A. Quintero
13 [GO] 2022―Feb―26 Self-medication and the ‘infodemic’ during mandatory preventive isolation due to the COVID-19 pandemic Andrés Gaviria-Mendoza, Danny Alberto Mejía-Mazo, Carolina Duarte-Blandón, Juan Daniel Castrillón-Spitia, Manuel Enrique Machado-Duque, Luis Fernando Valladales-Restrepo, Jorge Enrique Machado-Alba
14 [GO] 2021―Aug―26 Prediction of potential drug interactions between repurposed COVID-19 and antitubercular drugs: an integrational approach of drug information software and computational techniques data Levin Thomas, Sumit Raosaheb Birangal, Rajdeep Ray, Sonal Sekhar Miraj, Murali Munisamy, Muralidhar Varma, et al. (+4)
15 [GO] 2021―May―14 Renin-angiotensin-aldosterone system blockers and region-specific variations in COVID-19 outcomes: findings from a systematic review and meta-analysis Upinder Kaur, Sankha Shubhra Chakrabarti, Tejas K. Patel
16 [GO] 2021―Mar―15 Translating evidence into practice during the COVID-19 pandemic: pitfalls and mileages Arduino A. Mangoni, Gian Luca Erre
17 [GO] 2021―Feb―21 Routine use of immunosuppressants is associated with mortality in hospitalised patients with COVID-19 Phyo K. Myint, Ben Carter, Fenella Barlow-Pay, Roxanna Short, Alice G. Einarsson, Eilidh Bruce, et al. (+17)
18 [GO] 2021―Feb―13 Systematic review of immunosuppressant guidelines in the COVID-19 pandemic Fenella Barlow-Pay, Thura Win Htut, Mina Khezrian, Phyo Kyaw Myint
19 [GO] 2020―Sep―16 Hydroxychloroquine and chloroquine for COVID-19: psychiatric aspects of patient safety considerations Partha Sarathi Biswas, Devosri Sen
 [1] 

19 Results       Page 1


[de][en]

Last change 2025―Jul―29 14:55:09 UTC

© Daten-Quadrat 2022       Done in 0.005 sec